Essential oils derived from different plant species have revealed encouraging clinical and preclinical results to reverse cognitive and memory impairments in Alzheimer’s disease, a review study has found. The study, “Essential Oils as Treatment Strategy for Alzheimerʼs Disease: Current and Future Perspectives,” was published in the journal…
News
Alector’s candidate immune system-targeting therapy for Alzheimer’s disease, called AL002, will be evaluated for safety and tolerability in a first Phase 1 clinical trial, the company announced. AL002 is an antibody that targets and activates TREM2 (triggering receptor expressed on myeloid cells 2), a receptor selectively expressed on microglia — a group…
People with dementia, including those with Alzheimer’s disease, often are also living with one or more other chronic diseases that significantly impact their quality of life, according to a new study. The study, “The impact of comorbidity on the quality of life of people with dementia: findings from the…
Beta-amyloid’s Key Role in Alzheimer’s Toxic Clumps and Need for Personalized Medicine Focus of Talk
Increasing evidence places beta-amyloid aggregates at the center of the toxic protein clumps and neuroinflammation that drive Alzheimer’s, two experts in this disease said, and a personalized, combination treatment likely will be the best way of helping patients. These insights were shared at a recent Key Opinion Leader luncheon meeting,…
A retired U.S. executive has given $5 million to the University of Texas at San Antonio (UTSA) College of Sciences to establish a contest that challenges scientists to find the cause of Alzheimer’s disease, building on work begun by pioneering neuroscientist Oskar Fischer more than a century…
Chronic, low-level inflammation enhances the risk of Alzheimer’s disease among ApoE4 gene carriers, the major genetic risk factor for the late-onset form of the disorder, a study shows. The study, “Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers,” was published in the journal JAMA Network Open.
Herpes simplex virus type 1 (HSV1) may be linked to Alzheimer’s development, and antiviral therapies lower the risk of senile dementia in patients with severe herpes infections, according to a review study. The research, “Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease,”…
Continued activity improves physical health in older adults at risk of Alzheimer’s, which in turn can potentially reduce their risk of developing the disease, according to results of an Australian clinical trial. The study, “A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program…
Treatment with Anavex‘s investigational therapy Anavex 2-73 significantly reduces cognitive decline in people with Alzheimer’s disease and sustains their ability to perform daily activities, according to interim data from a Phase 2 extension study. Trial results were presented in a late-breaking oral presentation, titled “Longitudinal 148-Week Extension Study…
Neuralstem’s stem cell therapy for Alzheimer’s disease was found to improve cognition and lessen the load of amyloid-beta plaques in a mouse model of the disease, a study reports, recommending work continue into this possible Alzheimer’s treatment. The therapy, called NSI-532.IGF1, combines human neural stem cells with IGF1, a…
Recent Posts
- Study reports Alzheimer’s treatment gains in long-term care July 6, 2026
- Awareness month event has new name: Do What You Love to End Alzheimer’s June 1, 2026
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026